Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer

Prostate

Volumn 74, Issue 7, 2014, Pages 689-701

  Wang, Chunni ^a   Wang, Lin ^a,b   Su, Bo ^a   Lu, Ning ^a   Song, Jingjing ^a   Yang, Xiaoqing ^a   Fu, Weiwei ^a,c   Tan, Weiwei ^a   Han, Bo ^a,d  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c QINGDAO UNIVERSITY   (China)

^d SHANDONG UNIVERSITY   (China)

Author keywords

CTGF; EGFR; epithelial mesenchymal transition; prostate cancer; SPINK1

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN SPINK1; SERINE PROTEINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ARTICLE; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WOUND HEALING;

CTGF; EGFR; EPITHELIAL-MESENCHYMAL TRANSITION; PROSTATE CANCER; SPINK1;

CADHERINS; CARRIER PROTEINS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84898805795     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22787     Document Type: Article

References (56)

1. Vogelstein B, Kinzler KW,. Cancer genes and the pathways they control. Nat Med 2004; 10 (8): 789-799.
2. Shen MM, Abate-Shen C,. Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev 2010; 24 (18): 1967-2000.
3. Rubin MA, Maher CA, Chinnaiyan AM,. Common gene rearrangements in prostate cancer. J Clin Oncol 2011; 29 (27): 3659-3668.
4. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM,. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8 (7): 497-511.
5. Stenman UH,. Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development. Asian J Androl 2011; 13 (4): 628-629.
6. Huhtala ML, Pesonen K, Kalkkinen N, Stenman UH,. Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 1982; 257 (22): 13713-13716.
7. Soon WW, Miller LD, Black MA, Dalmasso C, Chan XB, Pang B, Ong CW, Salto-Tellez M, Desai KV, Liu ET,. Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med 2011; 3 (8): 451-464.
8. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, Hemminki A, Stenman UH, Bjartell A,. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol 2007; 52 (6): 1670-1679.
9. Solakidi S, Tiniakos DG, Petraki K, Stathopoulos GP, Markaki I, Androulakis G, Sekeris CE,. Co-expression of trypsin and tumour-associated trypsin inhibitor (TATI) in colorectal adenocarcinomas. Histol Histopathol 2003; 18 (4): 1181-1188.
10. Paju A, Jacobsen J, Rasmuson T, Stenman UH, Ljungberg B,. Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma. J Urol 2001; 165 (3): 959-962.
11. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andren O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM,. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008; 13 (6): 519-528.
12. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramaki OR, Visakorpi T,. Association of SPINK1 expression and TMPRSS2: ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 2010; 16 (10): 2845-2851.
13. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM,. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011; 3 (72): 72ra17.
14. Scheving LA, Primary amino acid sequence similarity between human epidermal growth factor-urogastrone human pancreatic secretory trypsin inhibitor, and members of porcine secretin family. Arch Biochem Biophys 1983; 226 (2): 411-413.
15. Bartelt DC, Shapanka R, Greene LJ,. The primary structure of the human pancreatic secretory trypsin inhibitor. Amino acid sequence of the reduced S-aminoethylated protein. Arch Biochem Biophys 1977; 179 (1): 189-199.
16. Ozaki N, Ohmuraya M, Hirota M, Ida S, Wang J, Takamori H, Higashiyama S, Baba H, Yamamura K,. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res 2009; 7 (9): 1572-1581.
17. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC,. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 2007; 67 (19): 9066-9076.
18. Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G, Liu ZR, Zhou BP, Huang WC, Chung LW,. Epithelial to mesenchymal transition (EMT) in human prostate cancer: Lessons learned from ARCaP model. Clin Exp Metastasis 2008; 25 (6): 601-610.
19. Kalluri R, Weinberg RA,. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119 (6): 1420-1428.
20. Thiery JP,. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2 (6): 442-454.
21. Nauseef JT, Henry MD,. Epithelial-to-mesenchymal transition in prostate cancer: Paradigm or puzzle ? Nat Rev Urol 2011; 8 (8): 428-439.
22. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310 (5748): 644-648.
23. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, Laxman B, Shah RB, Varambally S, Palanisamy N, Tomlins SA, Kumar-Sinha C, Chinnaiyan AM,. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008; 68 (18): 7629-7637.
24. Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z, Han B,. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro. Prostate Cancer Prostatic Dis 2013. 16 (4): 301-307.
25. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB,. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009; 22 (8): 1083-1093.
26. Tian W, Wang G, Yang J, Pan Y, Ma Y,. Prognostic role of E-cadherin and vimentin expression in various subtypes of soft tissue leiomyosarcomas. Med Oncol 2013; 30 (1): 401.
27. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA,. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2 (2): 76-783.
28. Jhavar S, Brewer D, Edwards S, Kote-Jarai Z, Attard G, Clark J, Flohr P, Christmas T, Thompson A, Parker M, Shepherd C, Stenman UH, Marchbank T, Playford RJ, Woodhouse C, Ogden C, Fisher C, Kovacs G, Corbishley C, Jameson C, Norman A, De-Bono J, Bjartell A, Eeles R, Cooper CS,. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int 2009; 103 (9): 1256-1269.
29. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA,. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117 (7): 927-939.
30. Huber MA, Kraut N, Beug H,. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17 (5): 548-558.
31. Takahashi-Yanaga F, Kahn M,. Targeting Wnt signaling: Can we safely eradicate cancer stem cells ? Clin Cancer Res 2010; 16 (12): 3153-3162.
32. Grotendorst GR,. Connective tissue growth factor: A mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997; 8 (3): 171-179.
33. Quintas-Cardama A, Cortes J,. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113 (8): 1619-1630.
34. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM,. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79 (24): 7824-7827.
35. Ackland ML, Newgreen DF, Fridman M, Waltham MC, Arvanitis A, Minichiello J, Price JT, Thompson EW,. Epidermal growth factor-induced epithelio-mesenchymal transition in human breast carcinoma cells. Lab Invest 2003; 83 (3): 435-448.
36. Zuo JH, Zhu W, Li MY, Li XH, Yi H, Zeng GQ, Wan XX, He QY, Li JH, Qu JQ, Chen Y, Xiao ZQ,. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem 2011; 112 (9): 2508-2517.
37. Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y,. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 2010; 29 (35): 4947-4958.
38. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M, Kallioniemi O,. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2010; 70 (17): 6735-6745.
39. Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R,. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS ONE 2011; 6 (7): e21650.
40. Qi M, Yang XQ, Wang L, Zhang J, Wang Y, Han B,. Charcteristic analysis of ETS gene rearrangement in prostate cancer. J Shandong Univ 2013; 51 (6): 5.
41. Shi-Wen X, Leask A, Abraham D,. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 2008; 19 (2): 133-144.
42. Dhar A, Ray A,. The CCN family proteins in carcinogenesis. Exp Oncol 2010; 32 (1): 2-9.
43. Tong Z, Chen R, Alt DS, Kemper S, Perbal B, Brigstock DR,. Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes. Hepatology 2009; 50 (3): 939-947.
44. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR,. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005; 65 (19): 8887-8895.
45. Perbal B,. CCN proteins: Multifunctional signalling regulators. Lancet 2004; 363 (9402): 62-64.
46. Jiang CG, Lv L, Liu FR, Wang ZN, Na D, Li F, Li JB, Sun Z, Xu HM,. Connective tissue growth factor is a positive regulator of epithelial- mesenchymal transition and promotes the adhesion with gastric cancer cells in human peritoneal mesothelial cells. Cytokine 2013; 61 (1): 173-180.
47. Zhang C, Meng X, Zhu Z, Liu J, Deng A,. Connective tissue growth factor regulates the key events in tubular epithelial to myofibroblast transition in vitro. Cell Biol Int 2004; 28 (12): 863-873.
48. Urtasun R, Latasa MU, Demartis MI, Balzani S, Goni S, Garcia-Irigoyen O, Elizalde M, Azcona M, Pascale RM, Feo F, Bioulac-Sage P, Balabaud C, Muntane J, Prieto J, Berasain C, Avila MA,. Connective tissue growth factor autocriny in human hepatocellular carcinoma: Oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology 2011; 54 (6): 2149-2158.
49. Mao X, Yu Y, Boyd LK, Ren G, Lin D, Chaplin T, Kudahetti SC, Stankiewicz E, Xue L, Beltran L, Gupta M, Oliver RT, Lemoine NR, Berney DM, Young BD, Lu YJ,. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res 2010; 70 (13): 5207-5212.
50. Lee K, Chae JY, Kwak C, Ku JH, Moon KC,. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology 2010; 76 (5): 1268.e7-1268.e13.
51. Kimura T, Furusato B, Miki J, Yamamoto T, Hayashi N, Takahashi H, Kamata Y, van Leenders GJ, Visakorpi T, Egawa S,. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients. Pathol Int 2012; 62 (11): 742-7748.
52. Bismar TA, Yoshimoto M, Duan Q, Liu S, Sircar K, Squire JA,. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology 2012; 60 (4): 645-652.
53. Lippolis G, Edsjo A, Stenman UH, Bjartell A,. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells. Prostate Cancer Prostatic Dis 2013; 16 (2): 145-150.
54. Alshalalfa M, Bismar TA, Alhajj R,. Detecting cancer outlier genes with potential rearrangement using gene expression data and biological networks. Adv Bioinform 2012; 2012: 373506.
55. Bhalla R, Kunju LP, Tomlins SA, Christopherson K, Cortez C, Carskadon S, Siddiqui J, Park K, Mosquera JM, Pestano GA, Rubin MA, Chinnaiyan AM, Palanisamy N,. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. Mod Pathol 2013; 26 (6): 835-848.
56. Grupp K, Diebel F, Sirma H, Simon R, Breitmeyer K, Steurer S, Hube-Magg C, Prien K, Pham T, Weigand P, Michl U, Heinzer H, Kluth M, Minner S, Tsourlakis MC, Izbicki JR, Sauter G, Schlomm T, Wilczak W,. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. Prostate 2013; 73 (15): 1690-1698.